Neuronetics, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: STIM · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1227636
| Field | Detail |
|---|---|
| Company | Neuronetics, Inc. (STIM) |
| Form Type | DEF 14A |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Executive Compensation, Director Election, Auditor Ratification
TL;DR
<b>Neuronetics, Inc. will hold its virtual Annual Meeting of Stockholders on May 30, 2024, to elect directors, ratify auditors, and vote on executive compensation.</b>
AI Summary
Neuronetics, Inc. (STIM) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Annual Meeting scheduled for May 30, 2024, held virtually via live webcast. Agenda includes election of five director nominees, ratification of KPMG LLP as independent auditor, and advisory votes on executive compensation and its frequency. Stockholders of record or beneficial owners as of April 1, 2024, at 5:00 p.m. ET are eligible to attend and vote. Definitive Proxy Statement filed on April 11, 2024. Company headquarters located at 3222 Phoenixville Pike, Malvern, PA.
Why It Matters
For investors and stakeholders tracking Neuronetics, Inc., this filing contains several important signals. The meeting will address key governance matters, including director elections and auditor ratification, which are crucial for investor confidence and regulatory compliance. Advisory votes on executive compensation and its frequency allow stockholders to voice their opinions on the company's pay practices and governance structure.
Risk Assessment
Risk Level: low — Neuronetics, Inc. shows low risk based on this filing. The filing is a routine DEF 14A proxy statement, indicating standard corporate governance procedures rather than significant financial or operational changes.
Analyst Insight
Stockholders should review the proxy statement to understand the director nominees, auditor selection, and executive compensation proposals before the May 30th meeting.
Key Numbers
- 5 — Director Nominees (Number of nominees for director to be elected at the Annual Meeting.)
- May 30, 2024 — Annual Meeting Date (Date of the virtual Annual Meeting of Stockholders.)
- 5:00 p.m. Eastern Time — Record Date Time (Time on April 1, 2024, to determine stockholder eligibility.)
- April 1, 2024 — Record Date (Date to determine eligibility to attend and vote at the Annual Meeting.)
Key Players & Entities
- Neuronetics, Inc. (company) — Registrant name
- KPMG LLP (company) — Independent registered public accounting firm
- May 30, 2024 (date) — Date of Annual Meeting
- April 1, 2024 (date) — Record date for Annual Meeting eligibility
- 3222 Phoenixville Pike, Malvern, Pennsylvania 19355 (address) — Company address
FAQ
When did Neuronetics, Inc. file this DEF 14A?
Neuronetics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Neuronetics, Inc. (STIM).
Where can I read the original DEF 14A filing from Neuronetics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Neuronetics, Inc..
What are the key takeaways from Neuronetics, Inc.'s DEF 14A?
Neuronetics, Inc. filed this DEF 14A on April 11, 2024. Key takeaways: Annual Meeting scheduled for May 30, 2024, held virtually via live webcast.. Agenda includes election of five director nominees, ratification of KPMG LLP as independent auditor, and advisory votes on executive compensation and its frequency.. Stockholders of record or beneficial owners as of April 1, 2024, at 5:00 p.m. ET are eligible to attend and vote..
Is Neuronetics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Neuronetics, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A proxy statement, indicating standard corporate governance procedures rather than significant financial or operational changes.
What should investors do after reading Neuronetics, Inc.'s DEF 14A?
Stockholders should review the proxy statement to understand the director nominees, auditor selection, and executive compensation proposals before the May 30th meeting. The overall sentiment from this filing is neutral.
How does Neuronetics, Inc. compare to its industry peers?
Neuronetics, Inc. operates in the medical device industry, specifically focusing on neurostimulation for treating medical conditions.
Are there regulatory concerns for Neuronetics, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the information required in proxy statements for shareholder meetings.
Industry Context
Neuronetics, Inc. operates in the medical device industry, specifically focusing on neurostimulation for treating medical conditions.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the information required in proxy statements for shareholder meetings.
What Investors Should Do
- Review the list of director nominees and their qualifications.
- Evaluate the company's rationale for selecting KPMG LLP as the independent auditor.
- Consider the advisory proposals on executive compensation and its frequency before casting your vote.
Key Dates
- 2024-05-30: Annual Meeting of Stockholders — To elect directors, ratify auditors, and vote on executive compensation.
- 2024-04-01T17:00:00.000Z: Record Date — Determines eligibility to attend and vote at the Annual Meeting.
- 2024-04-11: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a definitive proxy statement typically filed annually to provide information for the upcoming shareholder meeting.
Filing Stats: 4,670 words · 19 min read · ~16 pages · Grade level 11 · Accepted 2024-04-11 16:02:20
Filing Documents
- ny20018124x1_def14a.htm (DEF 14A) — 631KB
- ny20018124x1_pc01.jpg (GRAPHIC) — 603KB
- ny20018124x1_pc02.jpg (GRAPHIC) — 355KB
- ny20018124x1_pvp01x1.jpg (GRAPHIC) — 148KB
- ny20018124x1_pvp02x1.jpg (GRAPHIC) — 107KB
- sig_wandrewmacan.jpg (GRAPHIC) — 17KB
- 0001140361-24-019350.txt ( ) — 2325KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 21 EXECUTIVE OFFICERS OF THE COMPANY ​ ​ 23
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 24 PROPOSAL 3 - ADVISORY VOTE ON EXECUTIVE COMPENSATION ​ ​ 32 PROPOSAL 4 - ADVISORY VOTE ON FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON EXECUTIVE COMPENSATION ​ ​ 33 DIRECTOR COMPENSATION ​ ​ 34 TRANSACTIONS WITH RELATED PERSONS ​ ​ 35 OTHER MATTERS ​ ​ 37 i TABLE OF CONTENTS NEURONETICS, INC. 3222 Phoenixville Pike, Malvern, Pennsylvania 19355   PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS April 11, 2024   INTRODUCTION The 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Neuronetics, Inc. (“Neuronetics,” “we,” “us,” “our,” and the “Company”) will be held virtually on Thursday, May 30, 2024 at 8:00 a.m. Eastern Time. To attend and participate in the Annual Meeting, stockholders of record will need to visit virtualshareholdermeeting.com/STIM2024 and use their 16-digit control number received in their notice (their “Control Number”) to log in to this website. Beneficial owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds their shares. We encourage stockholders to log in to this website and access the webcast before the start time of the Annual Meeting. 1 TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING What is the purpose of this proxy statement? The Board of Directors of the Company (the “Board of Directors” or the “Board”) is soliciting a proxy from each holder of our common stock to vote on the items to be considered at the Annual Meeting, scheduled to take place on Thursday, May 30, 2024, or at any adjournment or postponement of the Annual Meeting. We are first mailing or making available to stockholders this proxy statement an